Retrospektivna analiza liječenja bolesnika s kroničnim C hepatitisom pegiliranim interferonom i ribavirinom u tercijarnoj zdravstvenoj ustanovi

master's thesis

• Title (english): Retrospective cohort study of pegylated interferon and ribavirin in the treatment of hepatitis C in tertiary health care
• Author: Ava Marušić
• Mentor: Ivica Grgurević (mentor)
• Committee member: Ivica Grgurević
• Committee member: Vesna Bačić Vrca
• Committee member: Maja Ortner Hadžiabdić
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; Zagreb
• Defense date and country: 2015-09-17, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Hepatitis C veliki je javnozdravstveni problem i jedan od glavnih uzroka transplantacije jetre, stoga se pokušava pronaći optimalna terapija za liječenje navedene bolesti. U KB Dubrava u periodu od 2007. do 2013. godine za liječenje kroničnog hepatitis C koristila se dvojna terapija ribavirina i pegiliranog interferona. Tokom navedenog perioda skupljena je skupina od 39 pacijenata čija dokumentacija je prikupljena i obrađena u ovom radu. Iz dostupnih podataka ispitala se zastupljenost genotipova u populaciji te stupanj izlječivosti pojedinih genotipova. Ishod liječenja proučavan je kroz brzi virološki odgovor (vrijednosti HCV 12 tjedana nakon terapije), virološki odgovor na kraju terapije te kroz trajni virološki odgovor (6 mjeseci nakon završetka liječenja). Studija je pokazala da su u populaciji češće bili zastupljeni genotipovi 1 i 4, međutim trajni virološki odgovor postignut je u znatno većem postotku kod genotipova 2 i 3, pa je tako tek 36% pacijenata s genotipom 1 i 4 postiglo trajni virološki odgovor, dok je on kod genotipa 2 i 3 iznosio 64,28%. Nuspojave su bile češće kod starije populacije, a liječenju su pristupali pacijenti s visokom viremijom i značajnom fibrozom.
Iako je studija napravljena na samo 39 ispitanika njezini rezultati u skladu su s rezultatima objavljenim u stručnoj literaturi.

Abstract (english)

Hepatitis C is a global health problem. In a period of five years combination of interferon and ribavirin was used in Clinical Hospital Dubrava as a therapy for hepatitis C. This therapy was used by 39 patients in Clinical Hospital Dubrava whose medical documentation was researched in this study. We investigated the most popular genotypes in the population and the efficiency and safety of this therapy. The efficiency of therapy was measured trough the number of people that had sustained viral response. Study shows that genotypes 1 and 4 were more frequent in the population but people with genotypes 2 and 3 had a better response to the treatment. Only 36% of patients with genotypes 1 and 4 and 64.28% of patients with genotypes 2 and 3 had SVR. This therapy had serious side effects such as anemia, pancytopenia, leukocytopenia etc. Due to the side effects some of the patients had to stop using their therapy. Better response to the therapy, with less side effects, was among younger people and among people with lower viral load.
Although it includes only 39 patients, this study shows almost the same results as other similar studies that investigates efficiency and safety of interferon and ribavirin therapy.

• Keywords: hepatitis C; ribavirin; interferon; genotip
• Keywords (english): hepatitis C; ribavirin; interferon; genotypes
• Language: croatian
• URN:NBN: urn:nbn:hr:163:878752
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Access restricted to students and staff of home institution
• Created on: 2016-02-11 13:50:05